



ORHUB, INC.

**OTC PINK BASIC ANNUAL INFORMATION
AND DISCLOSURE STATEMENT**

AS OF JUNE 30, 2017

ORHUB, INC.

OTC PINK BASIC ANNUAL INFORMATION AND DISCLOSURE STATEMENT

AS OF JUNE 30, 2017

The Company

On June 30, 2016, MemReg, Inc. (the “*Company*”) acquired all the assets and business of ORhub, LLC (“*ORH*”) in exchange for 102,694,775 shares of common stock and assumption of certain ORH liabilities (the “*Acquisition*”). ORH was developing a proprietary, 100% cloud based software application for the management of implantable devices and biologic components (the “*ORhub Software*”). As a condition of the closing of the Acquisition, the Company divested its memorabilia business operated through its wholly owned subsidiary, Memorabilia Registry Corp. (“*MRC*”), through a tax-free split-off of MRC (the “*Split-off*”). To affect the Split-off, certain stockholders exchanged all the Company’s outstanding Series C Preferred stock and 9,447,602 shares of common stock for all the outstanding capital stock of MRC. As a result of the Acquisition and contemporaneous divestiture of MRC, since July 1, 2016, the Company has focused on the development of the ORhub business. Effective on February 9, 2017, the Company received regulatory approval to change its name to ORhub, Inc., a name change filed and accepted by Nevada on August 22, 2016. With that February 9, 2017 approval, FINRA authorized a symbol change from MREG to ORHB.

The Company’s Business

Starting with the acquisition of ORH, the Company became a medical software company focused on delivering case-based data analytics at the speed of surgery. The Company's suite of products serves the needs of the health care industry, hospital, patient, government and the medical device vendor. The Company provides a cloud-based software solution that captures information before, during and after surgery, filling a void in the current surgical information infrastructure and providing the first process to capture and measure the surgical process -- evolving mass siloed data into Intelligent Digital Data.

The Company’s software applications allow hospitals and medical device vendors to utilize any web-enabled device to create an anatomical graphic depiction of exactly what occurs during surgery. The ORhub application automatically translates the resulting schematic into an intelligent, electronic operative report that links every detail of surgery, including implant location, surgical techniques, product usage, serial numbers and all clinical parameters to create a dynamically new source of comparative information.

As a result, hospitals and surgeons can make real-time, data driven decisions to improve business profitability and the quality of patient care. This innovative technology results in hospitals understanding costs and identifying areas of cost reductions, as well as results in increased accountability, automatic creation of comprehensive anatomic implant registries, real-time analytics, improved efficiencies, and compliance with existing government regulations.

In March 2017, the Company was in full production with its spine service line having added the capacity to track sterilization. By July 2017, the Company had launched its orthopedic service lines which marks the first two of 10 major expansions expected for 2017, representing ORhub's ability to

ORHUB, INC.

OTC PINK BASIC ANNUAL INFORMATION
AND DISCLOSURE STATEMENT
AS OF THE YEAR ENDING JUNE 30, 2017

advance its service line roadmap and execute its broader expansion strategy. With the upcoming release of Brain, Heart, General, Gastro Intestinal, Cardiology, Interventional Radiology, Gynecological Oncology, and Plastics service lines, ORhub is proving that its platform is effective for all surgeries, putting the Company one step closer to its goal of gathering data from 100 million surgeries per year.

The Company teamed with two major hospitals to refine its product and service line modules. Its initial module targeted spine surgeries since they are so complex. The ORhub System has a powerful and intuitive graphical interface, and the ability to track implants and other materials used in surgery from the point of delivery for a case through the billing cycle and into outcome correlation metrics. Data is captured during a surgery and uploaded to the Company's "cloud" for processing in a secure and HIPPA compliant manner.

The Software is completed and in use daily

The Company is beyond the risk that its software will not be operational. The Company picked the most complex implant surgery, spine implants, to fully developed its software. The Company is currently planning on fully deploying two other service line modules by December 2017. All other implants are less complex than spines, but with very similar process flows and data elements. To date, the Company has processed in excess of 2,000 surgeries and this count is increasing daily.

Prior history and development of Issuer

The Company was originally incorporated in Arizona on September 3, 2004 under the name VT Gaming Services, Inc. ("VTG") to implement the confirmed Chapter 11 Bankruptcy Plan (the "Plan") of Visitalk.com, Inc. (the "Debtor"). At the time of confirmation of the Plan, VTG was capitalized with a license to the Debtor's technology with use limited to facilitate peer-to-peer computer gaming activities. Pursuant to the Plan, creditors and claimants of the Debtor received stock and warrants in VTG (see Items 3(A)2(a) and 3(C) below).

On December 31, 2004, pursuant to an Exchange Agreement, the Company acquired all of the outstanding capital stock of DynaSig Corporation, an Arizona corporation ("*DynaSig*"). Reflecting this change in business, in 2005 the Company changed its name to Dynamic Biometric Systems, Inc. and changed its state of incorporation from Arizona to Nevada. In 2009, the Company refocused on the memorabilia business by forming MRC. In December 2013, the Company restructured its operations by selling DynaSig and focusing on the memorabilia business.

On June 30, 2016, the Company acquired the assets of ORH and contemporaneously Split-off the shares of MRC.

ITEM 1) NAME OF THE ISSUER AND ITS PREDECESSORS (IF ANY)

Effective August 22, 2016, the Company changed its name and on February 9, 2017 received regulatory approval to implement the name change in its trading. Thereafter, FINRA authorized a symbol change from MREG to ORHB. In April 2011, the Company had changed its name from Dynamic Biometric Systems, Inc. ("*DYBO*") to MemReg, Inc. This name change was approved at the opening of business January 2, 2015 when the Company's trading symbol was changed from DYBO to

ORHUB, INC.

OTC PINK BASIC ANNUAL INFORMATION
AND DISCLOSURE STATEMENT
AS OF THE YEAR ENDING JUNE 30, 2017

MREG. Effective December 31, 2004, the Company changed its name from VT Gaming, Inc., an Arizona corporation, to DYBO when it changed its state of domicile to Nevada from Arizona.

ITEM 2) ADDRESS OF THE ISSUER'S PRINCIPAL EXECUTIVE OFFICES

Company Headquarters

Address 1: 9830 South 51st Street
Address 2: Suite A-128
Address 3: Phoenix, AZ 85044
Phone: (844)545-4508, ext. 403
Email: info@orhub.com
Corporate website: www.orhub.com

IR Contact: NetworkNewsWire (NNW)
Address 1: 1324 Lexington Ave.
Address 2: Suite 117
Address 3: New York, NY
Phone: (212) 418.1217
Email: editor@NetworkNewsWire.com
Corporate website: www.NetworkNewsWire.com

ITEM 3) SECURITY INFORMATION

A. Exact title and class of securities outstanding: **Common Stock**
Trading Symbol: ORHB
CUSIP: 68620R 107
Par or Stated Value: \$.001
Total shares authorized: 190,000,000 as of: 6/30/2017
Total shares outstanding: 128,716,527 as of: 6/30/2017
Total shares reserved: 43,637,191 as of: 6/30/2017

Transfer Agent for the Common stock

Name: Computershare Trust Company, NA.
Address 1: 8742 Lucent Boulevard
Address 2: Suite 255
Address 3: Highlands Ranch, Colorado 80219
Phone: (303) 262-0678

Is this Transfer Agent registered under the Exchange Act?* Yes: No:

List any restrictions on the transfer of security:

1. Restricted - A majority of the shares of common stock currently outstanding were issued in private transactions or without other exemptions and are therefore restricted securities requiring a registration or exemption from registration to be "free trading."

2. Non-Restricted

(a) *Prior to June 30, 2016.* Pursuant to the Plan confirmed in 2004, in which the Company was a co-proponent, approximately 220,000 shares were issued to non-affiliates. In 2005, 124,125 shares of common stock and in 2014, 130,466 shares of common stock were issued through the exercise of Plan Warrants (see Item 3C below). These shares of common stock issued pursuant to the Plan and the exercise of the Plan Warrants were issued pursuant to Section 1145 of the Bankruptcy Code and are “free trading.”

(b) *Year ending June 30, 2017.* On July 8, 2016, the Company established a Special Exercise Price of the Plan Warrants of \$.3333 (See Plan Warrants under C of this section). During the nine months ended March 31, 2017, 10,554,273 Plan Warrants were exercised at the Special Exercise Price and the Company received proceeds of \$3,517,730 in cash and notes. The shares of common stock issued pursuant to exercise of these Plan Warrants was exempt from registration pursuant to Section 1145 of the Bankruptcy Code and are “free trading.”

B. Additional class of securities: **Undesignated Preferred**

Trading Symbol:	none
CUSIP:	no CUSIP – n/a
Par or Stated Value:	to be determined by the Board of Directors
Total shares authorized:	7,775,827 as of: 3/31/2017
Total shares designated	NONE

Preferred Stock Transfer Agent

Name:	<u>If designated</u> , the Company will act as its own transfer agent
Address 1:	9830 South 51st Street, Suite A-128
Address 2:	Phoenix, AZ 85044
Phone:	(844) 545-4508, ext. 403

Is the Transfer Agent registered under the Exchange Act?* Yes: No:

List any restrictions on the transfer of security:

All previously designated series of Preferred stock have been withdrawn and now there are no designated classes of preferred stock.

C. Additional class of securities: **Convertible Debenture**

On May 1, 2017, the Company authorized a Master Note Agreement covering the issuance of up to \$5,000,000 in Convertible Debentures (the “*Debentures*”). The Debentures bear interest at 12% per annum, accrued quarterly, and payable in cash or stock at the option of the Company. The Company can set a different conversion price, currently at \$.40, for future issuances and may or may not enhance the issue with “*Warrant Coverage*.” The Debentures currently have a June 30, 2020 due date but may be prepaid at any time. A holder has the option to convert at any time. Currently the Company is offering warrants with the Debentures (the “*Debenture Warrants*”) with Warrant Coverage equal to 30% of the conversion shares, exercisable at \$.50 per Debenture Warrant. The Debenture Warrants expire on June 30, 2021. The Debenture Warrants are immediately detachable. The

Company may modify future Debenture Warrants as to exercise price, maturity or percentage coverage of Debentures sold.

Trading Symbol:	NONE
CUSIP:	no CUSIP – n/a
Par or Stated Value:	Face value of the Notes issued
Total Debentures authorized:	\$5,000,000 as of: 6/30/2017
Total Debentures issued	\$678,300 as of: 6/30/2017

Convertible Debenture Transfer Agent

Name:	The Company will act as its own transfer agent
Address 1:	9830 South 51st Street, Suite A-128
Address 2:	Phoenix, AAZ 85044
Phone:	(844) 545-4508, ext. 403

Is the Transfer Agent registered under the Exchange Act?*

Yes:

No:

Restrictions on transfer – The Debentures currently outstanding were issued in private transactions or without other exemptions and are therefore restricted securities requiring a registration or exemption from registration to be “free trading.” The Debentures are convertible into common shares which bear the same restrictions as the Debenture.

D. Additional class of securities:

Debenture Warrants

Trading Symbol:	NONE
CUSIP:	no CUSIP – n/a
Par or Stated Value:	Face value of the Notes issued
Total Debenture Warrants authorized:	3,750,000 as of: 6/30/2017
Total Debentures Warrants issued	508,725 as of: 6/30/2017
Exercise price:	\$.50
Expiration date:	June 30, 2021

Convertible Debenture Transfer Agent

Name:	The Company will act as its own transfer agent
Address 1:	9830 South 51st Street, Suite A-128
Address 2:	Phoenix, Arizona 85044
Phone:	(844) 545-4508, ext. 403

Is the Transfer Agent registered under the Exchange Act?*

Yes:

No:

Restrictions on transfer – The Debenture Warrants currently outstanding were issued in private transactions or without other exemptions and are therefore restricted securities requiring a registration or exemption from registration to be “free trading.” Upon exercise, the Debenture

Warrants are convertible into common shares which bear the same restrictions as the Debenture Warrants.

E. Additional class of securities: **Plan Warrants**

The Company has five series of common stock purchase warrants outstanding allowing holders to purchase additional shares of common stock. All these warrants were issued under the Plan (“*Plan Warrants*”). Each Plan Warrant provides for the purchase of one share of common stock and is callable at any time by the Company for a price of \$.0001 per warrant. The Plan Warrants are governed by a Warrant Agreement. Currently, the Company is acting as the Warrant Agent but has the right to appoint an alternative Warrant Agent in accordance with the Warrant Agreement. Pursuant to the Plan, the Company’s Board of Directors can extend the expiration date of the Plan Warrants or reduce the exercise price of any Plan Warrant on a temporary or permanent basis.

Pursuant to the Warrant Agreement, without Company approval, a holder may not exercise Warrants which when combined with current beneficial ownership would increase such holder’s ownership in the Company above 5%. On August 1, 2016, in response to a request, the Company waived the 5% ownership restriction for six large shareholders who owned greater than 5% of the Company in exchange for undertakings regarding current information to meet the Company’s disclosure requirements.

A summary of the Warrants outstanding as of June 30, 2017, is as follows:

	<u>Series B Warrants</u>	<u>Series C Warrants</u>	<u>Series D Warrants</u>	<u>Series E & F Warrants</u>
Warrants outstanding, June 30, 2016	8,293,025	8,423,491	8,423,491	16,846,982
Exercised	3,754,362	2,382,089	1,669,787	2,748,033
Expired	-	-	-	-
Warrants outstanding, June 30, 2017	<u>4,538,663</u>	<u>6,041,402</u>	<u>6,753,704</u>	<u>14,098,949</u>
Exercise price (1)	<u>\$.50</u>	<u>\$ 3.00</u>	<u>\$.50</u>	<u>\$ 4.00</u>
Warrant Expiration date	<u>Dec. 31, 2017</u>	<u>Dec. 31, 2017</u>	<u>Dec. 31, 2017</u>	<u>Dec. 31, 2017</u>

(1) On July 8, 2016, the board of directors approved reducing the exercise price of all Plan Warrants to \$.3333 (the “*Special Exercise Price*”) which initially expired on October 6, 2016. The board of directors extended the Special Exercise Price until December 5, 2016 but only for the Series B Plan Warrants. The Special Exercise was extended again for all Plan Warrants until February 27, 2017. During the eight months ended February 27, 2017, 10,554,273 Plan Warrants were exercised at the Special Exercise Price and the Company received proceeds of \$3,517,730 in cash and notes for cash and notes. On February 28, 2017, the Plan Warrants reverted to their original exercise prices. On June 21, 2017 the board of directors approved reducing the exercise price of just the B&D Plan Warrants to \$.50 (the “*B&D Special Exercise Price*”) until they are exercised or expire on December 31, 2017.

1. Exact title and class of securities outstanding: **Plan Warrant Unit**

Originally approved by the Plan, the Company determined that the Plan Warrant Unit was impractical and was not be renewed upon its expiration on December 31, 2016. The Unit has been permanently detached into its components; i.e. Plan Warrants Series B, C, D, E and F.

2. Exact title and class of securities outstanding: **Series B Plan Warrants**

Trading Symbol: none

CUSIP: 68620R 115– transferable but no trading market

Par or Stated Value: Exercise price maximum \$.50 or as adjusted downward as determined by the Board of Directors

Total Series B Plan Warrants authorized: 4,538,663 as of: 6/30/2017. No additional Series B Warrants can be authorized and therefore the shares reserved equals the outstanding Series B Plan Warrants.

3. Exact title and class of securities outstanding: **Series C Plan Warrants**

Trading Symbol: none

CUSIP: 68620R 123 – transferable but no trading market

Par or Stated Value: Exercise price maximum \$3.00 or adjusted downward as determined by the Board of Directors

Total Series C Plan Warrants authorized: 6,041,402 as of: 6/30/2017. No additional Series C Warrants can be authorized and therefore therefore the shares reserved equals the outstanding Series C Plan Warrants.

4. Exact title and class of securities outstanding: **Series D Plan Warrants**

Trading Symbol: none

CUSIP: 68620R 131– transferable but no trading market

Par or Stated Value: Exercise price maximum \$.50 or adjusted downward as determined by the Board of Directors

Total Series D Plan Warrants authorized: 6,753,704 as of: 6/30/2017. No additional Series D Warrants can be authorized and therefore therefore the shares reserved equals the outstanding Series D Plan Warrants.

5. Exact title and class of securities outstanding: **Series E Plan Warrants**

Trading Symbol: none

CUSIP: 68620R 149 – transferable but no trading market

Par or Stated Value: Exercise price maximum \$4.00 or adjusted downward as determined by the Board of Directors

Total Series E Plan Warrants authorized: 7,005,308 as of: 6/30/2017. No additional Series E Warrants can be authorized and therefore the shares reserved equals the outstanding Series E Plan Warrants.

6. Exact title and class of securities outstanding: **Series F Plan Warrants**

Trading Symbol: none

CUSIP: 68620R 156 – transferable but no trading market

Par or Stated Value: Exercise price maximum \$4.00 or adjusted downward as determined by the Board of Directors
 Total Series F Plan Warrants authorized: 7,093,639 as of: 6/30/2017. No additional Series F Warrants can be authorized and therefore the shares reserved equals the outstanding Series F Plan Warrants.

Transfer Agent for all Series of Plan Warrants

Name: ORhub, Inc. (the Company acts as its own transfer agent for all Series of Plan Warrants)
 Address 1: 9830 S. 51st Street, Suite A-128
 Address 2: Phoenix, AZ 85044
 Phone: (844)545-4508, ext. 403

Is the Transfer Agent registered under the Exchange Act?* Yes: No:

List any restrictions on the transfer of security:

All the Plan Warrants (the Series B through Series F Plan Warrants) and any shares of common stock issued to non-affiliates through their exercise are unrestricted securities as provided under Section 1145 of the Bankruptcy Code. Shares of common stock issued to affiliates through their exercise may be subject to Rule 144 and, in particular, the “dribble” rule.

F. Describe any trading suspension orders issued by the SEC in the past 12 months.

None

G. List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On June 30, 2016, the Company acquired the assets of ORH and Split-off MRC. This is outside the 12-month window specified above. No other stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization has taken place since June 30, 2016.

ITEM 4) ISSUANCE HISTORY

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years.

Reconciliation Table of items changing outstanding shares of common stock:

1. Common shares outstanding at December 31, 2014	20,051,436
2. Common shares issued for debt (see Detail 4-2 below)	3,400,000
3. Common shares issued for ORH Assets (see 4-3 below)	102,694,775
4. Less: Shares returned to the Treasury (see 4-4 below)	<u>(9,447,603)</u>
5. Total shares outstanding at June 30, 2016	116,698,608
6. Common shares issued in private placements	538,563

	(see 4-6 below)	
7.	Common shares issued for settlements and services (see 4-7 below)	925,085
8.	Common shares issued for Plan Warrant exercises (see 4-8) below	10,554,271
9.	Total shares outstanding at June 30, 2017	128,716,527

The items on the Reconciliation Table are presented in more detail below and include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The listing shall indicate the nature of the issuance, the jurisdiction and distribution, the shares offered or issued, the shares finally issued and their price, the trading status of the shares issued and if they are restricted.

Issuance 4-2 from the Reconciliation Table

- A. Nature of the issuance. On September 1, 2015, the Company converted approximately \$285,600 of debt into 3,400,000 shares of common stock valued at \$.084. These securities were issued under Section 4(2) of the Securities Act of 1933.
- B. Jurisdictions and distribution. Issuances specified in Section 4-2 were limited private offerings made in reliance on the exemption for registration provided under Section 4(2) of the Securities Act of 1933;
- C. Shares offered. 3,400,000 shares of common stock to retire debt (see 4-1 above);
- D. Shares sold. 3,400,000 shares of common stock to retire debt (see 4-1 above);
- E. Price offered and sold. The 3,400,000 shares of common stock issued to retire debt were issued for \$.084 per share;
- F. Trading status. The 3,400,000 shares of common stock are restricted securities
- G. Legend. Yes, the 3,400,000 shares of common stock issued to retire debt were issued with a restrictive legend

Issuance 4-3 from the Reconciliation Table

- A. Nature of the issuance. On June 30, 2016, under the terms of an Asset Purchase Agreement (the “APA”), the Company acquired all the assets and assumed certain liabilities of ORhub, including its name, business, technology, website, and intellectual property. The Company issued 102,694,775 shares of its common stock, representing 88.0% of the common stock of the Company at the closing of the APA. For accounting purposes, ORhub will be deemed to be the accounting acquirer in the transaction and, consequently, the transaction will be treated as a recapitalization of the Company. As a result of this accounting treatment, ORhub’s financial statements, with required adjustments, become the historical financial statements of the Company and the Company’s assets, liabilities, and results of

operations are consolidated with ORhub effective as of the date of the closing of the APA. No step-up in basis or intangible assets or goodwill will be recorded in this transaction. These securities were issued under Section 4(2) of the Securities Act of 1933.

B. Jurisdictions and distribution. Issuances specified in Issuance 4-3 were limited private offerings made in reliance on the exemption for registration provided under Section 4(2) of the Securities Act of 1933 and made only to ORhub, LLC;

C. Shares offered. 102,694,775 shares of common stock to acquire assets (see 4-3 above);

D. Shares sold. 102,694,775 shares of common stock to acquire assets (see 4-3 above);

E. Price offered and sold. The 102,694,775 shares of common stock issued to acquire the assets was a tax-free, assets for stock exchange with no attributable price to the buyer.

F. Trading status. The 102,694,775 shares of common stock are restricted securities

G. Legend. Yes, the 102,694,775 shares of common stock issued to acquire the assets and business of ORhub, LLC and such shares were issued with a restrictive legend

Retirement 4-4 from the Reconciliation Table

A. Nature of the issuance. On June 30, 2016, as a condition of the Asset Purchase Agreement (the “APA”), the Company “split-off” its Memorabilia Registry Corp. (“MRC”) wholly owned subsidiary in exchange for the return to the Company’s Treasury of 9,447,603 shares of common stock and all the outstanding Series C Preferred shares. All these shares were returned to the Company’s treasury.

B. Jurisdictions and distribution. Issuances specified in Retirement 4-4 were limited private offerings made in reliance on the exemption for registration provided under Section 4(2) of the Securities Act of 1933 and made only to select shareholders of the Company.

C. Shares offered to be acquired. 9,447,603 shares of common stock to acquire the shares of MRC (see 4-4 above) and all the outstanding Series C Preferred shares;

D. Shares surrendered. 9,447,603 shares of common stock to acquire the shares of MRC (see 4-4 above) and all the outstanding Series C Preferred shares;

E. Price offered and sold. The 9,447,603 shares of common stock issued to acquire the assets was a tax-free split-off with the retention by the MRC recipients of some Company shares. The Company recognized no additional gain or loss on this transaction for book purposes.

F. Trading status. The 9,447,603 shares of common stock returned to treasury are no longer tradable.

G. Legend. n/a

Issuance 4-6 from the Reconciliation Table

A. Nature of the issuance. On June 30, 2016, under the terms of the APA, the Company assumed ORH's commitment to issue additional equity interests. The Company fulfilled that commitment by issuing 538,563 shares of common stock to a single buyer for \$161,569. These securities were issued under Section 4(2) of the Securities Act of 1933.

B. Jurisdictions and distribution. Issuances specified in Issuances 4-6 were limited private offerings made in reliance on the exemption for registration provided under Section 4(2) of the Securities Act of 1933 and Regulation D and made only to Accredited Investors as defined in Regulation D;

C. Shares offered. 538,563 shares of common stock (see 4-6 above);

D. Shares sold. 538,563 shares of common stock were acquired for cash (see 4-6 above);

E. Price offered and sold. The 538,563 shares of common stock were priced at \$.30 per share.

F. Trading status. The 538,563 shares of common stock are restricted securities

G. Legend. Yes, the 538,563 shares of common stock were issued with a restrictive legend

Issuance 4-7 from the Reconciliation Table

A. Nature of the issuances. During the period April 1, 2017 and June 30, 2017, the Company issued a total of 925,085 shares of common stock. 570,000 shares of common stock were issued for services, 342,316 shares of common stock were issued in the settlement of an employment claim and 12,769 shares were issued for interest payments on the Debentures.

B. Jurisdictions and distribution. Issuances specified in Issuance 4-7 were limited private offerings and issuances made in reliance on the exemption for registration provided under Section 4(2) of the Securities Act of 1933 and made only to specific non-related parties;

C. Shares offered. 925,085 shares of common stock (see 4-7 above);

D. Shares issued. 925,085 shares of common stock were acquired for non-cash consideration (see 4-7 above);

E. Price offered and sold. The 925,085 shares of common stock were priced at an average of \$.428 per share.

F. Trading status. The 925,085 shares of common stock are restricted securities

G. Legend. Yes, the 925,085 shares of common stock were issued with a restrictive legend

Issuance 4-8 from the Reconciliation Table

A. Nature of the issuance. Starting on July 8, 2016, pursuant to its rights under the Plan Warrants, the Board of Directors temporarily reduced the exercise prices of all the Plan Warrants to \$.3333. This "FY2017 Special Exercise Price" was extended various times through October 6, 2016. On that date,

ORHUB, INC.

the Board restricted the FY2017 Special Exercise Price to only the Series B Plan Warrants and the Series C through F Plan Warrants reverted to their original Plan exercise prices of \$3.00 and \$4.00. On December 6, 2016, the Board extended the FY2017 Special Exercise Price to all the Plan Warrant Series until February 27, 2017. On February 27, 2017, the Plan Warrants reverted to the Plan exercise price of \$2.00 through \$4.00 depending on the Series. On June 21, 2017, the Board of Directors temporarily reduced the exercise prices of the Series B and Series D Plan Warrants to \$.50 (the “FY2018 Special Exercise Price.”). During the year ended June 30, 2017, 10,554,271 Plan Warrants were exercised at the FY2017 Special Exercise Price and the Company received proceeds of \$3,517,729 in cash and notes for cash and notes. Any securities issued through the exercise of any of the Plan Warrants are issued under Section 1145 of the Bankruptcy Code.

- B. Jurisdictions and distribution. Any issuances specified in Issuance 4-7 through the exercise of any of the Plan Warrants were issued under Section 1145 of the Bankruptcy Code;
- C. Shares offered. 10,554,271 shares of common stock were issued due to warrant exercises (see 4-8 above);
- D. Shares exercised (sold). 10,554,271 shares of common stock purchase warrants were exercised for cash and notes (see 4-8 above);
- E. Price paid for exercise. \$.3333 per share was paid in cash and notes for the 10,554,271 shares of common stock issued through exercise of the Plan Warrants;
- F. Trading status. The 10,554,271 shares of common stock are free trading securities pursuant to Section 1145 of the Bankruptcy Code; and
- G. Legend. Since the securities are free trading they were issued without and restrictive legend

ITEM 5) FINANCIAL STATEMENTS – UNAUDITED (*)

As discussed in Item 4-3 of the Reconciliation table above, ORhub is deemed to be the acquirer in the Acquisition. Therefore, ORhub’s operations are deemed to have commenced at its date of inception, November 12, 2015. Because of this treatment, the financial statements for the year ended June 30, 2017 are not comparable with the financial statements for the year ended June 30, 2016. These financial statements were prepared in accordance with US GAAP.

ORhub, Inc. – Unaudited Financial Statements – June 30, 2017 (*)	Page
Balance Sheets (unaudited) as of June 30, 2017 and 2016	F-3
Statements of Operations (unaudited) for the year ended June 30, 2017 and for the period from November 12, 2015 (date of inception) to June 30, 2016	F-4
Statements of Stockholder’s Equity (Deficit) (unaudited) for the year ended June 30, 2017 and for the period from November 12, 2015 (date of inception) to June 30, 2016	F-5
Statements of Cash Flows (unaudited) for the year ended June 30, 2017 and for the period from November 12, 2015 (date of inception) to June 30, 2016	F-6
Notes to the Financial Statements (unaudited) as of June 30, 2017	F-8

(*) **Filed separately and incorporated herein by reference**

ITEM 6) DESCRIBE THE ISSUER'S BUSINESS, PRODUCTS AND SERVICES

A. A description of the issuer's business operations:

The Company's Business

Starting with the acquisition of ORH, the Company became a medical software company focused on delivering case-based data analytics at the speed of surgery. The Company's suite of products serves the needs of the health care industry, hospital, patient, government and the medical device vendor. The Company provides a cloud-based software solution that captures information before, during and after surgery, filling a void in the current surgical information infrastructure and providing the first process to capture and measure the surgical process -- evolving mass siloed data into Intelligent Digital Data.

The Company's software applications allow hospitals and medical device vendors to utilize any web-enabled device to create an anatomical graphic depiction of exactly what occurs during surgery. The ORhub application automatically translates the resulting schematic into an intelligent, electronic operative report that links every detail of surgery, including implant location, surgical techniques, product usage, serial numbers and all clinical parameters to create a dynamically new source of comparative information.

As a result, hospitals and surgeons can make real-time, data driven decisions to improve business profitability and the quality of patient care. This innovative technology results in hospitals understanding costs and identifying areas of cost reductions, as well as results in increased accountability, automatic creation of comprehensive anatomic implant registries, real-time analytics, improved efficiencies, and compliance with existing government regulations.

In March 2017, the Company was in full production with its spine service line having added the capacity to track sterilization. By July 2017, the Company had launched its orthopedic service lines which marks the first two of 10 major expansions expected for 2017, representing ORhub's ability to advance its service line roadmap and execute its broader expansion strategy. With the upcoming release of Brain, Heart, General, Gastro Intestinal, Cardiology, Interventional Radiology, Gynecological Oncology, and Plastics service lines, ORhub is proving that its platform is effective for all surgeries, putting the Company one step closer to its goal of gathering data from 100 million surgeries per year.

The Company teamed with two major hospitals to refine its product and service line modules. Its initial module targeted spine surgeries since they are so complex. The ORhub System has a powerful and intuitive graphical interface, and the ability to track implants and other materials used in surgery from the point of delivery for a case through the billing cycle and into outcome correlation metrics. Data is captured during a surgery and uploaded to the Company's "cloud" for processing in a secure and HIPPA compliant manner.

The Software is completed and in use daily

The Company is beyond the risk that its software will not be operational. The Company picked the most complex implant surgery, spine implants, to fully developed its software. The Company is currently planning on fully deploying two other service line modules by December 2017. All other

ORHUB, INC.

OTC PINK BASIC ANNUAL INFORMATION
AND DISCLOSURE STATEMENT
AS OF THE YEAR ENDING JUNE 30, 2017

implants are less complex than spines, but with very similar process flows and data elements. To date, the Company has processed in excess of 2,000 surgeries and this count is increasing daily.

The Company's Market

The Company believes the customer base for the ORhub Software is readily identifiable. There are approximately 5,600 hospitals in the United States. But, the top 12 hospital ownership groups control roughly 20% of the market. Initially, because of the Company's extensive access to these top-tier markets through our Surgical Business and Technical Advisory Board and the Company's development partners, we intend to focus our marketing efforts on these groups and initially on those hospitals considered leaders in spine surgery related to the aging spine, degenerative disc disease, and complex reconstructive deformity procedures. The Company believes that by penetrating this target group, other less complex market segments will more readily follow.

- B. Date and State (or Jurisdiction) of Incorporation: September 8, 2005/Nevada
- C. the Company's primary and secondary SIC Codes: 7372
- D. the Company's fiscal year end date: June 30
- E. principal products or services, and their markets: The Company is continuing to develop software that it intends to monetize by selling per use or other subscriptions for the software

ITEM 7) DESCRIBE THE ISSUER'S FACILITIES

We sub-lease approximately 500 square feet of administrative office space in Phoenix, Arizona through February 2018. We lease a development office in Bellevue, Washington in an executive suite. We have entered an 18-month lease for 873 square feet which commenced January 1, 2017 and expires on June 30, 2018. The Company believes additional and alternative office space is readily available.

ITEM 8) OFFICERS, DIRECTORS, AND CONTROL PERSONS

A. Names of Officers, Directors, and Control Persons.

1. Management

Colton Melby, Chief Executive Officer
Lanny R. Lang, Chief Financial Officer
Wesley Mitchell, Chief Technical Officer
Stephen Verstraete, VP Engineering

2. Board of Directors

Colton Melby, Chairman of the Board
Corey Lambrecht, Director

3. Surgical Business and Technical Advisory Board and Control Persons

ORHUB, INC.

The Surgical Business and Technical Advisory Board (the “Advisory Board”) is elected by the CEO for a one-year term ending June 30, 2018. The Advisory Board Members are compensated by a non-statutory option grant vesting over two years.

Lin M.D., Dr. Eric L.
Dobkin, Dr. William (Company Control Person)
Lee, Dr. Richard (Company Control Person)
Wiggins, Christopher (Company Control Person)
Beyer M.D., Dr. Alan H.
Binder, Dr. Devin K.
Brant-Zawadzki, Dr. Michael N.
Brown, Dr. John V.
Haskell, Dr. Richard J.
Holnagel, Ms. Dori
Moscowitz, James F.
Massoudi M.D., Dr. Farzad
Peck M.D., Dr. Wallace W.
Raney, Dr. Aidan A.
Zusman, Dr. Douglas R.
Afile, Dr. Rick
Dennis, Dr. Steve

B. Legal/Disciplinary History. None of our Officers, Directors or Control Persons have, in the last five years, been the subject of: (1) A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses); (2) The entry of an order, judgment, or decree, not subsequently reversed, suspended, or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person’s involvement in any type of business, securities, commodities, or banking activities; (3) A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or (4) The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person’s involvement in any type of business or securities activities.

C. Beneficial Stockholders. The following table sets forth the name, address, and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the Company’s equity securities.

Beneficial Ownership Table
(as of June 30, 2017)

Name of Beneficial Owner	Number of Shares Beneficially Owned	Percentage Beneficially Owned (1)
Colton Melby (2) 12025 DE OR Drive, Dallas, TX 75230	17,203,018	13.3%
Christopher Wiggins (3) (5) 15785 Laguna Canyon Road, Suite 125, Irvine, CA 92618	21,946,436	17.0%
William Dobkin, MD (4) (5) Hoag Neuroscience Institute c/o Dr. William Dobkin, 3900 W. Coast Hwy, Suite 300, Newport Beach, CA 92663	24,979,014	19.4%
Richard Lee, MD (5) Hoag Orthopedic Institute c/o Dr. Richard Lee 16250 Sand Canyon Ave., Irvine, CA 92618	15,275,384	11.9%
Wesley Mitchell (6) 10900 NE 4th Street, Suite 2430, Bellevue, WA 98004	16,578,018	12.9%

Footnotes to the Beneficial Ownership Table

- (1) Based on 128,716,530 shares of our common stock outstanding.
- (2) This includes 16,578,018 shares held by Castillo de Coachella, LLC, beneficially owned by Mr. Melby and includes all 625,000 vested stock options held by Castillo Misterio, LLC with a \$.33 exercise price beneficially owned by Mr. Melby.
- (3) This includes 21,833,936 shares held by Wylde, LLC, beneficially owned by Mr. Wiggins and this includes Mr. Wiggins' 112,500 vested stock options for his Advisory Board Service with exercise prices between \$.33 and \$.50.
- (4) This includes 24,866,514 shares held by JAATRL, LLC, beneficially owned by Dr. Dobkin and this includes all Dr. Dobkin's 112,500 vested stock options for his Advisory Board Service with exercise prices between \$.33 and \$.50.
- (5) This includes 15,162,884 shares held by OR Lstock, L.L.C. and beneficially owned by Dr. Lee and also includes all Dr. Lee's 112,500 vested stock options for his Advisory Board Service with exercise prices between \$.33 and \$.50.
- (6) All these shares are held by Sudden Valley, LLC., beneficially owned by Mr. Mitchell.

ITEM 9) THIRD PARTY PROVIDERS (these are Company's only 3rd party providers)

1. Legal Counsel:
Firm: Sherman & Howard L.L.C
Contact: Thomas J. Morgan
Address 1: 201 East Washington Street, Suite 800

Address 2: Phoenix, Arizona 85004
Phone: (602) 240-3000
Email: tmorgan@shermanhoward.com

2. Accountant:

Name: Malone & Bailey LLP.
Contact: Jimmy Thompson
Address 1: 9801 Westheimer Rd., Suite 1100
Address 2: Houston, Texas 77042
Phone: (713) 343-4246
Email: jthompson@malonebailey.com

ITEM 9) THIRD PARTY PROVIDERS (continued)

3. Investor Relations and Communications Contact:

Name: NetworkNewsWire (NNW)
Contact: Michael McCarthy
Address 1: 1324 Lexington Ave., Suite 117
Address 2: New York, New York 10128
Phone: (212) 418.1217
Email: editor@NetworkNewsWire.com
Website: www.NetworkNewsWire.com

ITEM 10) ISSUER CERTIFICATION

Certifications by the chief executive officer and chief financial officer of the Issuer.

A. Chief Executive Officer Certification

I, Colton Melby, certify that:

1. I have reviewed this ORhub, Inc.'s Quarterly Disclosure Statement for the Company's fiscal year ending June 30, 2017;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

/s/ Colton Melby
Colton Melby,
Chief Executive Officer

October 13, 2017
Date

ITEM 10) ISSUER CERTIFICATION (CONTINUED)

B. Chief Financial Officer Certification

I, Lanny R. Lang, certify that:

1. I have reviewed this ORhub, Inc.'s Quarterly Disclosure Statement for the Company's fiscal year ending June 30, 2017;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

/s/ Lanny R. Lang
Lanny R. Lang,
Chief Financial Officer

October 13, 2017
Date